Phideli Pharmaceutical

Phideli Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on discovering and developing innovative small molecule therapeutics. The company specializes in targeting the ubiquitin-proteasome system (UPS), specifically deubiquitinating enzymes (DUBs), to treat cancer and other serious diseases. Its lead candidate, PDI-101, is a potent and selective USP7 inhibitor currently undergoing clinical evaluation for patients with advanced solid tumors and hematological malignancies. Phideli leverages a team with deep expertise from major global pharmaceutical companies to advance a pipeline of precision medicines. By focusing on challenging protein-protein interactions and novel mechanisms of action, the company aims to provide transformative therapies for patients with high unmet medical needs.